H. Lee Moffitt Cancer Center and Research Institute: Leukemia, Myeloid, Acute trials
The registry lists 13 Leukemia, Myeloid, Acute studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 3 are open to participants now and 6 have results posted.
Phase 1 6Phase 2 7No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- BCL2i CLAG-M in R/R Acute Myeloid LeukemiaRecruitingNCT06660368Phase 2
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDRecruitingNCT06511882Phase 2
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
- Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
- CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT00955916Phase 2Results posted
- Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
- Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction ChemotherapyCompletedNCT00387647Phase 2Results posted
- Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell TransplantationTerminatedNCT00363467Not applicableResults posted
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCTActive, not recruitingNCT05015426Phase 1
- Quality of Life Model for Older Patients With AMLActive, not recruitingNCT04380441
- Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03760523Phase 1
- A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1